Suche

Programmdetails

Postervorträge

TAVI bei AK-Stenose: Biomarker

Freitag, 25. April | 09:45 - 10:45 Uhr | Posterbereich 13

Vorsitz/Chair: Harald Lapp (Bad Berka), Victor Mauri (Köln)

Agenda

(P954)
Patientencharakteristika und Outcomes in TAVI-Patienten mit hohem (>50mg/dl) vs. niedrigem Lipoprotein(a), eine Analyse aus dem Breisgau-TAVI-Register
T. Maulhardt (Freiburg im Breisgau)
Zum Abstract
(P955)
Regulatory long non-coding RNAs and their potential roles in aortic diseases
A. M. Utami (Bonn)
Zum Abstract
(P956)
Elucidation of Long non-coding RNA in epigenetic regulation in aortic disease and their potential therapeutic role
J. I. Muñoz-Manco (Bonn)
Zum Abstract
(P957)
sST2 and mosaic loss of Y-chromosome: a combined biological-genomic prognostic marker related to fibrosis in aortic valve stenosis
S. Mas-Peiro (Frankfurt am Main)
Zum Abstract
(P958)
Regulatory long non-coding RNAs and their potential role as intercellular messengers in aortic disease
A. M. Utami (Bonn)
Zum Abstract
(P959)
Mutational landscape and impact of clonal hematopoiesis of indeterminate potential in severe aortic valve stenosis
R. N. Jamin (Bonn)
Zum Abstract
(P960)
Valvular Cyclophilin A expression indicates calcifying phenotypes of aortic stenosis
M. Sigle (Tübingen)
Zum Abstract
Diese Seite teilen